| Market News | | |
| |
| 1 (4) Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms Moderna beat fourth-quarter sales expectations and forecast growth for 2026, but an FDA refusal on its flu vaccine raises new concerns. (https://www.benzinga.com/) Fri. Feb 13, 2026 |
| 2 (5) Moderna Is Losing Less Money Than Expected. The Stock Jumps After Earnings. Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million. (https://www.barrons.com/) Fri. Feb 13, 2026 |
| 3 (8) Earnings live: Moderna stock pops on revenue growth, Rivian surges, Applied Materials jumps The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far. (https://finance.yahoo.com/) Fri. Feb 13, 2026 |
| 4 (-3) Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million. (https://www.barrons.com/) Fri. Feb 13, 2026 |
| 5 (-3) Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million. (https://www.barrons.com/) Fri. Feb 13, 2026 |
| |
| 6 (2) Moderna Sales Beat as Covid Shots Fall Less Than Expected Moderna Inc. beat fourth-quarter revenue estimates as its struggling Covid vaccines business declined less than expected. (https://www.bloomberg.com/) Fri. Feb 13, 2026 |
| 7 (5) Moderna beats quarterly revenue estimates on resilient sales of COVID shot Feb 13 () - Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U. The Cambridge, Massachusetts-based company has been struggling financially as demand for COVID vaccines collapsed in the years following its pandemic windfall. (https://finance.yahoo.com/) Fri. Feb 13, 2026 |